Curated News
By: NewsRamp Editorial Staff
January 16, 2025
ADVA Biotechnology and Cellipont Bioservices Collaborate to Showcase Automated CAR-T Manufacturing at Advanced Therapies Week 2025
Discuss on Reddit
Telegram
GithubTLDR
- Accelerate CAR-T production with ADVA X3® platform at Advanced Therapies Week 2025.
- ADVA X3® integrates in-process controls, AI, and machine learning for streamlined CAR-T manufacturing.
- ADVA X3® and Cellipont Bioservices collaboration brings life-saving cell therapies to patients faster and more reliably.
- ADVA X3® platform showcases seamless transition from R&D to GMP production with advanced controls and analytics.
Impact - Why it Matters
This news matters as it showcases how innovative technologies and collaborations can revolutionize cell therapy manufacturing, ultimately leading to faster and more reliable production of life-saving treatments for patients worldwide.
Summary
ADVA Biotechnology and Cellipont Bioservices are collaborating to showcase their successful transition of a CAR-T process from manual to automated at Advanced Therapies Week 2025 in Dallas. The showcase study highlights the capabilities of the ADVA X3® Cell Manufacturing Platform, emphasizing in-process controls, AI integration, and seamless R&D-to-GMP transition.
Source Statement
This curated news summary relied on this press release disributed by Reportable. Read the source press release here, ADVA Biotechnology and Cellipont Bioservices Collaborate to Showcase Automated CAR-T Manufacturing at Advanced Therapies Week 2025
